Raechel White

Dr. Raechel White

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 January 2023 in JACCP: Journal of the American College of Clinical Pharmacy
Verified
Journal Article
Closed access
RWRaechel White
Raechel White
ABAlexander J. Bos
Alexander J. Bos
JNJames J. Nawarskas
James J. Nawarskas
CRChelsea N. Rodriguez
Chelsea N. Rodriguez
EGElle Goldberg
Elle Goldberg
ABAllison Burnett
Allison Burnett

27 July 2024 in Journal of Pharmacy Technology
Verified
Journal Article
Closed access
BTBao Anh C. Tran
Bao Anh C. Tran
RWRaechel White
Raechel White
KBKrystal Bullers
Krystal Bullers
CCCyrille K. Cornelio
Cyrille K. Cornelio
Objective: This review provides an overview of the pharmacology, efficacy, and safety of sotagliflozin, a dual inhibitor of sodium-glucose cotransporters 1 and 2 (SGLT1 and SGLT2), to reduce the risk of cardiovascular death and hospitalization in those with heart failure. Data sources: A search of Embase via Elsevier, PubMed, Web of Science—All Databases, and The Cochrane Library for clinical trials in CENTRAL, as well as the MedRxiv and BioRxiv pre-print servers, was conducted from inception through December 1, 2023. Search terms included sotagliflozin, lx 4211, lp 802034, sar 439954, and (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol. Study selection and data extraction: Published phase 1, phase 2, and phase 3 clinical trials, meta-analyses, and systematic reviews. Studies were included if they were published in English and evaluated sotagliflozin pharmacology, pharmacokinetics, efficacy, or safety. Data synthesis: The Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure (SOLOIST-WHF) and Sotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk (SCORED) phase 3 trials compared sotagliflozin with placebo in patients with type 2 diabetes mellitus. In both the SCORED and SOLOIST-WHF trials, treatment with sotagliflozin resulted in a statistically significant reduction in the primary composite outcome of death from cardiovascular causes, hospitalizations due to heart failure (HF), and urgent visits for HF. Conclusions: Dual SGLT1 and SGLT2 inhibition with sotagliflozin is efficacious in reducing myocardial infarction (MI), stroke, and HF hospitalizations and urgent visits in the SCORED and SOLOIST-WHF trials. However, its impact on reducing cardiovascular mortality remains uncertain due to premature study discontinuation. Owing to these factors and lack of generalizability, further studies are needed to establish its role in renal protection and cardiovascular mortality in broader populations. At this time, more evidence is warranted to definitively establish sotagliflozin in HF.

13 October 2023 in Journal of the American Pharmacists Association
Verified
Journal Article
Closed access
MDMonica Douglas
Monica Douglas
RWRaechel White
Raechel White
KSKjersten Sankey
Kjersten Sankey
KAKelsea Gallegos Aragon
Kelsea Gallegos Aragon

21 February 2026 in Journal of Clinical Lipidology
Verified
Journal Article
Closed access
RWRaechel White
Raechel White
BABenedicta O. Ansong
Benedicta O. Ansong
KCKevin Cowart
Kevin Cowart

18 April 2023 in Cardiology in Review
Verified
Journal Article
Closed access
RWRaechel White
Raechel White
KSKjersten H. Sankey
Kjersten H. Sankey
JNJames J. Nawarskas
James J. Nawarskas
Chronically elevated low-density lipoprotein (LDL) has harmful effects on the vasculature including increased vasoconstriction and the formation of plaques which may rupture, causing coronary heart disease and stroke. In patients with familial hypercholesterolemia, adequate reduction of LDL is especially challenging. Although HMG-CoA reductase inhibitors (statins) are the mainstays for LDL lowering, other treatments such as proprotein convertase subtilisin/kexin type 9 inhibitors, bempedoic acid, incliseran, lomitapide, and apheresis have been employed in an effort to achieve adequate LDL reduction in these patients. Despite these available therapies, many patients with familial hypercholesterolemia do not meet the LDL targets suggested in current guidelines. Evinacumab is a novel lipid-lowering therapy that exerts its LDL-lowering effect through inhibition of angiopoietin-like protein 3 (ANGPTL3). ANGPTL3 inhibits the breakdown of triglyceride-rich lipoproteins, such as very low-density lipoprotein and chylomicrons. By inhibiting ANGPTL3, evinacumab allows these lipoproteins to be degraded, ultimately leading to reductions in LDL, high-density lipoprotein, and triglycerides. Clinical trials have demonstrated evinacumab to be safe and effective in reducing LDL. However, data are lacking regarding its potential to reduce risk of atherosclerotic cardiovascular disease. Evinacumab is generally well tolerated with the primary adverse effects comprising infusion reactions, nasopharyngitis, influenza-like illness, dizziness, rhinorrhea, and nausea. While evinacumab is an interesting therapy, until it is proven to reduce cardiovascular events, its high cost leaves its anticipated role in therapy somewhat ambiguous. In the meantime, it may be a useful therapy for those with homozygous familial hypercholesterolemia.

25 January 2025 in Currents in Pharmacy Teaching and Learning
Verified
Journal Article
Closed access
AEAmre A. Elmaoued
Amre A. Elmaoued
RRRotana M. Radwan
Rotana M. Radwan
OHOmar E. Hassan
Omar E. Hassan
MZMohammed Zaed
Mohammed Zaed
RWRaechel White
Raechel White